Chronic Lymphocytic Leukemia

CAR T-Cell Therapy Induces Response in NHL and CLL

An anti-CD19 chimeric antigen receptor (CAR) T-cell-transduced natural killer (NK) therapy induced responses in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL),...

Clinical Trial Participants vs. Medicare Beneficiaries Receiving Idelalisib: An Outcomes Analysis

A new study compared outcomes between relapsed follicular lymphoma and relapsed chronic lymphocytic leukemia patients treated with idelalisib in the clinical setting versus clinical...
FDA Extends Approval of Immunotherapy Agent Keytruda® to Include Esophageal Cancer

FDA Approves Second Drug Under New International Network Pathway for CLL/SLL

The U.S. Food and Drug Administration (FDA) granted supplemental approval to Calquence® (acalabrutinib) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The...

Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do...

Human leukocyte antigen B27 (HLA-B27), associated with spondyloarthritis, was suggested to be protective against chronic lymphocytic leukemia (CLL). It is hypothesized that HLA-B27 patients may have...
Combo Ibrutinib plus Venetoclax Treatment Effective in Relapsed CLL

Combo Ibrutinib plus Venetoclax Treatment Effective in Relapsed CLL

A study published in the Oct. 20 issue of the Journal of Clinical Oncology examined the effects of combination ibrutinib plus venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly...

Seventh Annual Society of Hematologic Oncology 2019 Meeting

DocWire News will provide coverage of the seventh annual Society of Hematologic Oncology Meeting (SOHO 2019), which will take place September 11–14, 2019, in Houston, TX
Bloodline: Familial Link Observed with Blood Cancers

Bloodline: Familial Link Observed with Blood Cancers

A study published in Blood found that having a parent, sibling, or child with blood cancer increases a person’s likelihood of being diagnosed with the disease.

Having Comorbid Cardiovascular Disease at Time of Cancer Diagnosis: Already One Step Behind When...

The relation between cardiovascular disease (CVD) present at the time of cancer diagnosis and Health-Related Quality of Life

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Abstract BACKGROUND: Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic...

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax).